/content/dam/genesiscare/centres-and-staff/uk-centres-and-staff/UK_Oncology_Centre_profile_GA_Oxford_4.jpeg
2024-12-12T00:00:00.000+00:00

GenesisCare becomes first UK private cancer care provider to offer Optune Gio®

GenesisCare becomes first UK private cancer care provider to offer Optune Gio®

UK’s leading independent specialist cancer care provider, GenesisCare becomes first UK private cancer care provider, to offer Optune Gio® as their standard of care for newly diagnosed WHO Grade 4 Glioma patients, through their partnership with global oncology company, Novocure

UK’s leading independent specialist cancer care provider, GenesisCare becomes first UK private cancer care provider, to offer Optune Gio® as their standard of care for newly diagnosed WHO Grade 4 Glioma patients, through their partnership with global oncology company, Novocure

Eligible patients can access Optune Gio® as part of their treatment for WHO Grade 4 Glioma in a streamlined process which means they will no longer have to self-advocate to their insurer for this treatment.

Optune Gio® is a portable CE marked medical device. Optune Gio® delivers alternating electric fields, called Tumour Treating Fields (“TTFields”). TTFields are delivered at a unique frequency that allows it to selectively disrupt Grade 4 Glioma cell division¹²³.  TTFields are delivered locally and non-invasively, directly at the tumour site via arrays that adhere to the skin.

A large phase 3 randomized controlled clinical trial showed that treatment with TTFields when used concomitantly with temozolomide (chemotherapy), extended median overall survival by 4.9months vs temozolomide alone without significantly compromising quality of life. Mild to moderate skin toxicity underneath the transducer arrays occurred in 52% of the patients who received TTFields + temozolomide in the trial4.

Dr Anup Vinayan – Clinical Director for Neuro-oncology at GenesisCare says: “Access has been the critical hurdle for newly diagnosed WHO Grade 4 Glioma patients.  We’re incredibly proud that at GenesisCare, patients covered with major insurers such as Bupa and Aviva, will no longer have to self-advocate for Optune Gio®, as we now can offer it as our standard of care for eligible patients after completion of chemoradiation in one of our centres.”

“Novocure is committed to advancing treatment for some of the most aggressive forms of cancer and we look forward to working with the teams at GenesisCare who are focused on achieving the best outcomes for people living with newly diagnosed WHO Grade 4 Glioma,” said Hilary Duckworth, General Manager UK & Ireland, Novocure. “Through this partnership, we are able to provide our treatment to more patients due to GenesisCare’s unique network of care centres throughout the UK.” 

For more information about GenesisCare and its comprehensive cancer care services, please visit www.genesiscare.com/uk

Eligible patients can access Optune Gio® as part of their treatment for WHO Grade 4 Glioma in a streamlined process which means they will no longer have to self-advocate to their insurer for this treatment.

Optune Gio® is a portable CE marked medical device. Optune Gio® delivers alternating electric fields, called Tumour Treating Fields (“TTFields”). TTFields are delivered at a unique frequency that allows it to selectively disrupt Grade 4 Glioma cell division¹²³.  TTFields are delivered locally and non-invasively, directly at the tumour site via arrays that adhere to the skin.

A large phase 3 randomized controlled clinical trial showed that treatment with TTFields when used concomitantly with temozolomide (chemotherapy), extended median overall survival by 4.9months vs temozolomide alone without significantly compromising quality of life. Mild to moderate skin toxicity underneath the transducer arrays occurred in 52% of the patients who received TTFields + temozolomide in the trial4.

Dr Anup Vinayan – Clinical Director for Neuro-oncology at GenesisCare says: “Access has been the critical hurdle for newly diagnosed WHO Grade 4 Glioma patients.  We’re incredibly proud that at GenesisCare, patients covered with major insurers such as Bupa and Aviva, will no longer have to self-advocate for Optune Gio®, as we now can offer it as our standard of care for eligible patients after completion of chemoradiation in one of our centres.”

“Novocure is committed to advancing treatment for some of the most aggressive forms of cancer and we look forward to working with the teams at GenesisCare who are focused on achieving the best outcomes for people living with newly diagnosed WHO Grade 4 Glioma,” said Hilary Duckworth, General Manager UK & Ireland, Novocure. “Through this partnership, we are able to provide our treatment to more patients due to GenesisCare’s unique network of care centres throughout the UK.” 

For more information about GenesisCare and its comprehensive cancer care services, please visit www.genesiscare.com/uk

References:

¹ Kirson ED, Dbalý V, Tovaryš F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007;104(24):10152-10157. doi:10.1073/pnas.0702916104

² Karanam NK, Story MD. An overview of potential novel mechanisms of action underlying tumor treating fields-induced cancer cell death and their clinical implications. Int J Radiat Biol. 2021;97(8):1044-1054. doi:10.1080/09553002.2020.1837984

³ Wenger C, Giladi M, Bomzon Z, Salvador R, Basser PJ, Miranda PC. Modeling Tumor Treating Fields (TTFields) application in single cells during metaphase and telophase. Annu Int Conf IEEE Eng Med Biol Soc. 2015;2015:6892-6895. doi:10.1109/EMBC.2015.7319977

4 Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial Citation: Stupp R, et al. JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718. PMID: 29260225

 

About GenesisCare UK:

GenesisCare UK is the UK’s leading cancer care provider, transforming cancer care with advanced diagnostics, medical oncology, radiotherapy and Theranostics. Operating 14 specialist outpatient centres, we provide patients with a world-class standard of care, and access to the latest innovative treatments proven to be safe and effective, delivered by highly trained physicians and healthcare professionals. With a philosophy of treating the whole patient not just the cancer, we take an integrated approach to cancer care.  Our personalised treatment programmes are supported with wellbeing services delivered through our unique partnership with the charity Penny Brohn UK. We provide exercise medicine, which is proven to deliver improved patient outcomes. In addition, we work with universities and leading clinicians around the world, to research and design new and better ways to treat cancers and have a growing UK clinical trials programme to support bringing new therapies to more patients. Treatments are available for patients with health insurance and those paying for their own care.

www.genesiscare.com/uk

 

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumour Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumour Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer.

Novocure’s global headquarters is located in Root Switzerland, with U.S. headquarters located in Portsmouth, New Hampshire and research and development facilities located in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.

Dr Anup Vinayan
Clinical Director for Neuro-oncology